We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Topical Antibiotics and Intravitreous Injections

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: December 13, 2006
Last Update Posted: November 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Christopher Ta, Stanford University
Evaluation of efficacy of topical preoperative antibiotics in patients undergoing intravitreous injections.

Condition Intervention Phase
Intravitreous Injections Drug: gatifloxacin Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other

Resource links provided by NLM:

Further study details as provided by Christopher Ta, Stanford University:

Primary Outcome Measures:
  • Positive Culture [ Time Frame: Study day 1, assessed following administration of study treatment ]
    The percentage of patients with a positive bacterial culture following administration of study treatment is presented.

Enrollment: 129
Study Start Date: July 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: topical antibiotic
topical gatifloxacin 4 times per day
Drug: gatifloxacin


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • intravitreous injection

Exclusion Criteria:

  • antibiotic use
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00410891

United States, California
Stanford, California, United States, 94304
Sponsors and Collaborators
Stanford University
Principal Investigator: Christopher Ta, MD Stanford University
  More Information

Responsible Party: Christopher Ta, Principle Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT00410891     History of Changes
Other Study ID Numbers: 96803 (eProtocol 4384)
First Submitted: October 2, 2006
First Posted: December 13, 2006
Results First Submitted: May 13, 2014
Results First Posted: June 12, 2014
Last Update Posted: November 6, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents